NASDAQ$PTCT
PTC Therapeutics, Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
PTC Therapeutics reported first quarter financial results with a total revenue of $148.7 million, representing a 26% year-over-year growth. The company initiated the PIVOT-HD Phase 2 trial of PTC518 in Huntington’s disease and anticipates CHMP opinion on AADC gene therapy in May.
PTC Therapeutics announced its Q1 2022 financial results, highlighted by a 26% year-over-year revenue increase to $148.7 million. The DMD franchise and Evrysdi royalties drove revenue growth. The company is advancing its clinical pipeline with the initiation of a Phase 2 trial for Huntington's disease and expects a CHMP opinion on its AADC gene therapy soon.
- Total revenue reached $148.7 million, a 26% increase year-over-year.
- DMD franchise revenue totaled $128 million, driven by Translarna and Emflaza.
- Evrysdi royalties contributed $19 million to revenue.
- PIVOT-HD Phase 2 study of PTC518 for Huntington’s disease was initiated.
Headline financials
Revenue & EPS history
PTC Therapeutics · Revenue · Quarterly
$149M
Revenue by segment
PTC Therapeutics · $128M total across 2 segments · Q1 2022
- Translarna$79.2M+70.3%62.0%
- Emflaza$48.6M+11.7%38.0%
Forward guidance
PTC reaffirmed its 2022 financial guidance, expecting total revenues between $700 and $750 million and DMD franchise net product revenues between $475 and $495 million. GAAP R&D and SG&A expenses are projected to be between $915 and $965 million, while non-GAAP R&D and SG&A expenses are expected to range from $800 to $850 million.
Tailwinds
- Total revenues for full year 2022 are anticipated to be between $700 and $750 million.
- Net product revenues for the DMD franchise for full year 2022 are anticipated to be between $475 and $495 million.
- Continued geographic expansion of Translarna.
- Continued addition of new Emflaza patients.
- Advancement of clinical pipeline
Headwinds
- GAAP R&D and SG&A expenses for full year 2022 are anticipated to be between $915 and $965 million.
- Non-GAAP R&D and SG&A expense for full year 2022 are anticipated to be between $800 and $850 million, excluding estimated non-cash, stock-based compensation expense of $115 million.
- Risks in the development, regulatory approval and commercialization of new products.
- Uncertainties related to the COVID-19 pandemic.
- Dependence on regulatory approval in various territories.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-2.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+5.8%
Avg return
30 days after
46%
26 / 57 earnings
Positive
+24.1%
Q2 2016
Best reaction
-34.0%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +14.0% | +10.1% | |
| Q4 2025 | +1.1% | -3.1% | -6.6% | |
| Q3 2025 | -1.1% | +3.3% | +6.4% | |
| Q1 2025 | +12.8% | +27.1% | +44.0% | |
| Q4 2024 | +9.3% | +2.7% | +7.3% | |
| Q3 2024 | +2.5% | +3.3% | +11.3% | |
| Q2 2024 | -1.8% | +0.1% | -1.0% | |
| Q1 2024 | +13.3% | +27.5% | +47.6% | |
| Q4 2023 | +13.3% | +11.0% | +3.2% | |
| Q3 2023 | -20.5% | -19.5% | -6.9% | |
| Q2 2023 | -3.7% | -2.9% | -0.3% | |
| Q1 2023 | +5.6% | +5.2% | -18.3% | |
| Q4 2022 | -5.2% | -7.4% | -0.0% | |
| Q3 2022 | -15.7% | -17.3% | -12.9% | |
| Q2 2022 | +11.9% | +8.2% | +8.5% | |
| Q1 2022 | +1.5% | -7.8% | -24.9% | |
| Q4 2021 | -8.8% | -8.7% | -4.1% | |
| Q3 2021 | +7.0% | +12.4% | +7.4% | |
| Q2 2021 | -2.9% | -2.3% | +7.3% | |
| Q1 2021 | +0.3% | -1.3% | -5.6% | |
| Q4 2020 | -0.9% | -0.5% | -14.6% | |
| Q3 2020 | -0.5% | +8.4% | +22.0% | |
| Q2 2020 | -3.0% | -0.9% | -1.0% | |
| Q1 2020 | -10.3% | -7.9% | -5.3% | |
| Q4 2019 | -5.4% | +0.4% | -18.7% | |
| Q3 2019 | +1.9% | +2.4% | +16.8% | |
| Q2 2019 | +8.6% | +10.4% | +1.5% | |
| Q1 2019 | +1.4% | -1.2% | +10.5% | |
| Q4 2018 | +0.9% | -0.7% | +6.8% | |
| Q3 2018 | -12.4% | -14.9% | -13.4% | |
| Q2 2018 | +7.2% | +14.9% | +15.4% | |
| Q1 2018 | -4.7% | -2.6% | +22.8% | |
| Q4 2017 | +10.0% | +8.0% | -2.4% | |
| Q3 2017 | -1.9% | -5.2% | -11.2% | |
| Q2 2017 | -2.1% | -4.7% | +4.3% | |
| Q1 2017 | -3.8% | +6.6% | +26.3% | |
| Q4 2016 | -16.9% | -23.2% | -4.8% | |
| Q3 2016 | -34.0% | -11.2% | +74.5% | |
| Q2 2016 | +24.1% | +24.6% | +26.4% | |
| Q1 2016 | +1.7% | — | — | |
| Q4 2015 | -30.5% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | -11.2% | — | — | |
| Q4 2014 | -4.3% | — | — | |
| Q3 2014 | +3.3% | — | — | |
| Q2 2014 | -12.5% | — | — | |
| Q1 2013 | -5.7% | — | — | |
| Q1 2014 | -5.7% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q1 2012 | -8.4% | — | — | |
| Q4 2011 | -8.4% | — | — | |
| Q3 2012 | -10.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | +1.2% | — | — | |
| Q2 2012 | +1.2% | — | — | |
| Q4 2012 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro